Drug intelligence / Profile preview

cannabidiol-enriched cannabis oil

Development stage
Phase 3
Lead developer
Panaxia Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Sublingual
01

Overview

Cannabidiol-enriched cannabis oil is a pharmaceutical-grade phytocannabinoid formulation developed by Panaxia Pharmaceuticals for the treatment of intractable pediatric epilepsy. The formulation typically consists of a 20:1 ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) dissolved in olive oil. It acts on the endocannabinoid system by modulating cannabinoid receptors CB1 and CB2, as well as other non-cannabinoid targets such as GPR55 and TRPV1, to reduce neuronal hyperexcitability. Produced under Good Manufacturing Practice (GMP) protocols, it is administered as an oral or sublingual oil and has demonstrated efficacy in clinical studies for treatment-resistant epilepsy in children and adolescents.

Brand names
PANAXOLCANNDOCTikvaUltra HealthSALUS
Other names
CBD-enriched medical cannabis oil20:1 CBD:THC medical cannabis oil
02

Targets

CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on cannabidiol-enriched cannabis oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol-enriched cannabis oil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call